Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and 2026 first H Shareholders’ Class Meeting, all held on 27 February 2026.

The primary focus of these meetings was to consider special resolutions related to spinning off Fosun Adgenvax for a listing on the main board of the Hong Kong Stock Exchange. According to disclosed results, all resolutions presented at the EGM were approved. The H Shareholders’ Class Meeting passed the relevant resolution on providing assured entitlements, but the same resolution did not gain sufficient support at the A Shareholders’ Class Meeting. Consequently, assured entitlements will not be provided to any shareholders under the proposed spin-off. The announcement confirms that failure to pass the resolution in the A Shareholders’ Class Meeting does not affect proceeding with the spin-off plan.

The official poll tallies and legal opinion issued by the company’s PRC legal advisers confirm the legality and validity of all meeting procedures and voting outcomes. The announcement underscores that the proposed spin-off will continue without offering assured entitlements to any class of shareholders.